

CLINICAL DATA RESULTS ON SUBCUTANEOUS AND VISCERAL FAT-LOSS USING A DEVICE ULTRASOUND & EMS NARL 517 LIPOSTIMFIT.

Seishukai Medical Clinic (Osaka City)
Osaka Rosai Hospital (Sakai City, Osaka Prefecture)

Precaution

Unauthorized use of the images, numerical figures
and data in this document is prohibited.

NH LIMITED

OVERVIEW OF THE CLINICAL DATA

I	Purpose	To evaluate safety and effectiveness on fat-loss(subcutaneous and visceral fat)and local slimming(face and body)
I	Period	We performed the treatment twice a week on each subject for a period of five weeks from September 2 to October 4, 2024.
I	Subjects	Eight women aged 27 to 58 (average age: 42.3)
I	Device	NARL 517 LIPOSTIMFIT (Ultrasound and EMS) (NH LIMITED)
I	Gel	Genuine NARL517 LIPOSTIMFIT Gel Free Gel (NH LIMITED)
I	Measurement Items	<ul style="list-style-type: none">•X-ray CT imaging•Body composition analysis•Full-body imaging•Measurements (waist, naval and lower abdomen)
I	Measuring Devices	<ul style="list-style-type: none">•Abdominal CT tomographic image measurement: Asteion Super4 fully-body x-ray CT device (made by Toshiba Medical Systems) Taken at Seishukai Medical Clinic (Osaka City)•Body composition measurement: InBody970 body composition and component analyzer (made by Biospace) Taken at Osaka Rosai Hospital (Sakai City, Osaka Prefecture)
I	PROTOCOL	10 minutes NARL517 ultrasound & 60 minutes EMS on abdominal part - 10 minutes NARL517 on facial part Measuring devices used before / after each treatment



Asteion Super4




InBody970

ID001	Measurements(cm)			CT (Abdomen)		InBody			
Measurement date	Waist	Navel	Lower abdomen	Visceral fat	Girth of the abdomen(cm)	Body fat percentage (%)	Body fat mass (kg)	Weight (kg)	Skeletal mass (kg)
				Area (cm ²)					
2024/9/2	85.9	90.0	97.0	78.3	94.2	41.7	26.9	64.5	6.4
2024/10/4	78.8	84.9	89.7	46.7	91.2	41.1	26.4	64.2	6.5
Difference	-7.1	-5.1	-7.3	-31.6	-3.0	-0.6	-0.5	-0.3	0.1

■ Abdominal CT Tomographic Image Measurement

2024/9/2

2024/10/4



■ Abdominal Comparison Image

Right side

2024/9/2




2024/10/4



Left side

2024/9/2



2024/10/4



Front

2024/9/2



2024/10/4



■ Facial Comparison Image

Right side

2024/9/2



2024/10/4



Left side

2024/9/2



2024/10/4



■ Full-body Comparison Image

Front 2024/9/2



2024/10/4



Back 2024/9/2




2024/10/4




ID003	Measurements(cm)			CT (Abdomen)		InBody			
Measurement date	Waist	Navel	Lower abdomen	Visceral fat	Girth of the abdomen(cm)	Body fat percentage (%)	Body fat mass (kg)	Weight (kg)	Skeletal mass (kg)
				Area (cm ²)					
2024/9/2	85.8	91.1	82.6	70.7	93.7	32.9	22.3	67.9	7.1
2024/10/4	80.6	84.5	78.9	46.9	90.5	32.5	21.3	65.7	6.9
Difference	-5.2	-6.6	-3.7	-23.8	-3.2	-0.4	-1.0	-2.2	-0.2

■ Abdominal CT Tomographic Image Measurement

2024/9/2




2024/10/4



■ Abdominal Comparison Image

Right side

2024/9/2




2024/10/4




Left side

2024/9/2



2024/10/4



Front

2024/9/2



2024/10/4



■ Facial Comparison Image

Right side

2024/9/2



2024/10/4



Left side

2024/9/2




2024/10/4



■ Full-body Comparison Image

Front 2024/9/2

2024/10/4



Back 2024/9/2


2024/10/4




ID004	Measurements(cm)			CT (Abdomen)		InBody			
Measurement date	Waist	Navel	Lower abdomen	Visceral fat	Girth of the abdomen(cm)	Body fat percentage (%)	Body fat mass (kg)	Weight (kg)	Skeletal mass (kg)
				Area (cm ²)					
2024/9/2	97.9	104.5	103.4	213.8	105.3	42.1	32.3	76.6	6.9
2024/10/4	87.1	91.9	96.9	138.4	98.8	40.5	30.3	74.8	7.0
Difference	-10.8	-12.6	-6.5	-75.4	-6.5	-1.6	-2.0	-1.8	0.1

■ Abdominal CT Tomographic Image Measurement

2024/9/2



2024/10/4



■ Abdominal Comparison Image

Right side

2024/9/2



2024/10/4




Left side

2024/9/2




2024/10/4



Front

2024/9/2



2024/10/4



■ Facial Comparison Image

Right side

2024/9/2



2024/10/4




Left side

2024/9/2



2024/10/4



■ Full-body Comparison Image

Front 2024/9/2

2024/10/4



Back 2024/9/2

2024/10/4




ID005	Measurements(cm)			CT (Abdomen)		InBody			
Measurement date	Waist	Navel	Lower abdomen	Visceral fat	Girth of the abdomen(cm)	Body fat percentage (%)	Body fat mass (kg)	Weight (kg)	Skeletal mass (kg)
				Area (cm ²)					
2024/9/2	82.4	87.1	90.8	57.6	88.0	28.0	16.8	60.0	6.7
2024/10/4	71.7	81.0	83.3	47.9	83.7	26.2	15.4	58.7	6.8
Difference	-10.7	-6.1	-7.5	-9.7	-4.3	-1.8	-1.4	-1.3	0.1

■ Abdominal CT Tomographic Image Measurement

2024/9/2

2024/10/4



■ Abdominal Comparison Image

Right side

2024/9/2


2024/10/4



Left side

2024/9/2

2024/10/4



Front

2024/9/2



2024/10/4



■ Facial Comparison Image

Right side

2024/9/2



2024/10/4




Left side

2024/9/2



2024/10/4



■ Full-body Comparison Image

Front 2024/9/2



2024/10/4



Back 2024/9/2



2024/10/4




ID006	Measurements(cm)			CT (Abdomen)		InBody			
Measurement date	Waist	Navel	Lower abdomen	Visceral fat	Girth of the abdomen(cm)	Body fat percentage (%)	Body fat mass (kg)	Weight (kg)	Skeletal mass (kg)
				Area (cm ²)					
2024/9/2	76.9	81.6	85.0	107.3	85.6	39.8	24.6	61.9	5.9
2024/10/4	71.9	74.4	77.6	70.6	83.6	38.6	23.5	60.7	5.9
Difference	-5.0	-7.2	-7.4	-36.7	-2.0	-1.2	-1.1	-1.2	0.0

■ Abdominal CT Tomographic Image Measurement

2024/9/2


2024/10/4




■ Abdominal Comparison Image

Right side

2024/9/2




2024/10/4




Left side

2024/9/2




2024/10/4



Front

2024/9/2



2024/10/4



■ Facial Comparison Image

Right side

2024/9/2



2024/10/4



Left side

2024/9/2



2024/10/4



■ Full-body Comparison Image


Front 2024/9/2



2024/10/4



Back 2024/9/2




2024/10/4




ID007	Measurements(cm)			CT (Abdomen)		InBody			
Measurement date	Waist	Navel	Lower abdomen	Visceral fat	Girth of the abdomen(cm)	Body fat percentage (%)	Body fat mass (kg)	Weight (kg)	Skeletal mass (kg)
				Area (cm ²)					
2024/9/2	73.7	81.3	87.5	27.5	83.8	29.2	18.1	61.9	6.8
2024/10/4	71.3	76.3	81.8	21.8	82.4	28.2	17.1	60.7	6.7
Difference	-2.4	-5.0	-5.7	-5.7	-1.4	-1.0	-1.0	-1.2	-0.1

■ Abdominal CT Tomographic Image Measurement



■ Abdominal Comparison Image



Front

2024/9/2



2024/10/4



■ Facial Comparison Image

Right side

2024/9/2



2024/10/4



Left side

2024/9/2



2024/10/4




■ Full-body Comparison Image


Front 2024/9/2




2024/10/4



Back 2024/9/2



2024/10/4



General Remarks

We were able to confirm there was a partial slimming effect on the abdomen and face of the eight subjects despite the short period of five weeks from the results of the effectiveness test.

We performed the treatment using device (NARL517 LIPOSTIMFIT) twice a week for five weeks on eight subjects (women aged 27 to 58) in this test.

None of the subjects experienced poor physical health, skin troubles or other issues from using the test devices. Therefore, we confirmed that the device is safe.

We measured the waist, naval and lower abdomen of the subjects. We observed a reduction in size in all the subjects. In particular, the maximum average change in the naval circumference length was -6.7% (-5.7 cm) and the maximum change in an individual subject was -12.1% (-12.6 cm). We observed a decrease in fat (Subcutaneous fat and Visceral fat) in the areas treated by NARL 517 from these results. The perception of the subjects was proportional to the actual numerical figures obtained from the measurements.

We observed a reduction in visceral fat mass in the eight subjects from the measurement results. The average change was a decrease of -30.2% (-22.7 cm²). The maximum change in an individual subject was -35.3% (-75.4 cm²). These measurement results were consistent with the measurement data. Therefore, we were able to confirm that it was possible to obtain a partial slimming effect.

Body composition diagnosis using InBody is an effective diagnosis method because it focuses on skeletal muscle mass with the absence of a significant decrease in skeletal muscle serving as an indicator which makes it possible to confirm that excessive exercise and dietary restrictions were not imposed on the subjects in this test. Accordingly, we could confirm that the subjects generally maintain their muscle mass. In other words, the subjects were able to obtain a slimming effect from treatment with the device alone without excessive exercise or dietary restrictions. The above demonstrated that it is possible to obtain a slimming effect limited to the treated area using the NARL517 LIPOSTIMFIT.

NH LIMITED

Caution

◎ Appeals to general consumers based on the contents of this document may violate the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act). Use of the contents in this document for advertising and similar is prohibited.

◎ We hold the copyright to the text, photographs, diagrams and other contents of this document. Unauthorized use or reproduction is strictly prohibited.
